Saos-2 / Saos-2-luc Orthotopic Mouse Model Service for Sarcoma

The Saos-2 / Saos-2-luc orthotopic mouse model of sarcoma delivers a strongly osteoblastic human tumor directly into the tibial bone bed of immunodeficient mice, where it builds mineralizing, bone-forming primary tumors with measurable spread to lung and beyond. From authenticated cell expansion and intratibial implantation surgery to serial luciferase imaging, CT-based bone assessment and metastasis confirmation, Alfa Cytology delivers complete Saos-2 / Saos-2-luc orthotopic study programs configured around each sponsor’s compound, schedule and endpoint needs—exclusively within preclinical research.

Overview of Saos-2 / Saos-2-luc Orthotopic Mouse Model for Sarcoma

Saos-2 was established in 1973 by Jorgen Fogh from the osteogenic sarcoma of an 11-year-old Caucasian girl and has since become the benchmark human line for osteoblast biology. The cells carry a truncating TP53 mutation and produce no detectable p53 protein, which made them a favorite substrate for reconstitution studies of the p53 pathway; they are epithelial in appearance, adhere as a monolayer, and carry an aneuploid genome of roughly 56 chromosomes riddled with complex rearrangements. Their defining trait, however, is how faithfully they behave like osteoblasts: basal alkaline phosphatase activity is exceptionally high, receptors for 1,25-dihydroxyvitamin D₃ and parathyroid hormone are functional—the latter driving a robust cAMP response—and under osteogenic induction the cells deposit calcified nodules that stain with Alizarin Red while upregulating late markers such as SOST, DMP1, PHEX and MEPE. Intriguingly, these highly differentiated cells refuse to grow as subcutaneous tumors in immunocompromised mice, yet when placed directly into bone they engraft and progress, revealing how decisively the organ microenvironment governs their malignant expression.

Fig 1. Primary tumor BLI curves and IVIS SpectrumCT panels (BLI, lungs/spleen ex vivo, HES) of parental vs R/MTX vs R/DOXO orthotopic Saos-2-B-CDX and HOS-CDX models. (Marques da Costa, Maria Eugénia, et al., 2019)

In the orthotopic setting, a bone-adapted derivative of the line (Saos-2-B) carrying a lentiviral Luc2 luciferase reporter—often alongside the fluorescent mKate2 tag—is loaded into the proximal tibial cavity of immunodeficient mice, suspended in a small Matrigel volume that curbs immediate vascular washout. Engraftment is efficient (five of six NSG mice), bioluminescence is detectable within five days of implantation, and the primary tumor outgrows most comparator osteosarcoma xenografts, exceeding 10¹⁰ photon-scale signal by roughly six weeks in NSG animals. On CT the lesion is unmistakably osteoblastic: aberrant new bone condenses within and beyond the cortex, accompanied by periosteal reaction, cortical breach and only focal lysis—the mirror image of the predominantly osteolytic phenotype seen with other osteosarcoma lines. Pulmonary metastases appear between days 26 and 42 in NSG recipients, and unlike the usual pattern the model also delivers sporadic lesions to spleen and to the opposite, uninjected bone. Growth and spread are markedly slower in nude than in NSG hosts, and the immunodeficient requirement excludes immuno-oncology questions; within those boundaries the model excels for bone-matrix-targeting agents, mineralization and biomaterial evaluation, p53-pathway research, chemotherapy-resistance studies with methotrexate-adapted derivatives, and any program that needs a fast, faithfully osteoblastic primary tumor.

Cell Line Information: Saos-2 / Saos-2-luc

Saos-2 and its luciferase-labeled derivative Saos-2-luc descend from the same human osteogenic sarcoma; orthotopic studies typically employ the bone-adapted variant, and the reporter line additionally stably expresses firefly luciferase for quantitative optical tracking. Key characteristics are summarized below.

Our Services

Our ServicesOur ServicesBacked by in vivo oncology specialists and integrated imaging, surgical and pathology workflows, Alfa Cytology adapts every Saos-2 / Saos-2-luc orthotopic engagement to the sponsor’s scientific question—setting implantation conditions, imaging cadence and endpoint panels so that the model’s fast, faithfully osteoblastic kinetics resolve into clear, decision-grade preclinical findings.

Workflow of Saos-2 / Saos-2-luc Orthotopic Mouse Model Construction

Orthotopic construction of the Saos-2 / Saos-2-luc model is a survival-surgery workflow performed under inhalation anesthesia with pre-emptive analgesia, aseptic technique and disciplined post-operative observation, reflecting the model’s brisk growth in highly immunodeficient hosts. The procedure typically advances through the following stages:

1. Cell line qualification: Saos-2 or Saos-2-luc vials are mycoplasma-tested and STR-verified; reporter performance is confirmed in vitro by serial cell-titer bioluminescence titration with D-luciferin before expansion.
2. Animal preparation: immunodeficient mice (NSG preferred given superior engraftment; nude acceptable, typically 6–8 weeks old) are acclimatized under appropriate containment, health-screened and randomized by body weight ahead of surgery.
3. Anesthesia, analgesia and asepsis: mice receive isoflurane anesthesia with pre-emptive buprenorphine, the surgical leg is clipped and disinfected, and a sterile field with sterile instruments is maintained throughout.
4. Surgical exposure: a small incision over the knee exposes the proximal tibia, providing access to the medullary cavity under magnification.
5. Intratibial inoculation: Saos-2 / Saos-2-luc cells (typically 1.5 × 10⁶ in 10 µL Matrigel at 4 mg/mL) are injected into the proximal tibial cavity with a fine needle; the Matrigel suspension limits immediate spread into the circulation.
6. Closure and recovery: soft tissue and skin are closed with absorbable sutures and wound clips, post-operative analgesia is maintained, and gait, body weight and leg deformation are monitored on a defined schedule.
7. Longitudinal monitoring: primary tumor growth is tracked in vivo by weekly bioluminescence imaging after intraperitoneal D-luciferin for Saos-2-luc, with periodic CT scans documenting osteocondensation and cortical change; NSG cohorts frequently reach endpoint within 10–12 weeks.
8. Endpoint and analysis: at termination the tibial tumor is excised and weighed, lungs, spleen and contralateral bone are removed for ex vivo bioluminescence and metastasis counting, and tissues are processed for histology (including HES and luciferase staining), immunohistochemistry and molecular analysis.

Fig 2. Saos-2 / Saos-2-luc orthotopic mouse model construction workflow.

Case Study-Saos-2 / Saos-2-luc Orthotopic Mouse Model Development

Alfa Cytology curates a growing preclinical case-study collection for the Saos-2 / Saos-2-luc orthotopic platform, spanning establishment-phase refinement of inoculum and implantation conditions, longitudinal bioluminescence and CT tracking of osteoblastic primary tumors in vivo, bone-targeting and chemotherapy-resistance intervention studies, and systematic metastasis quantification across lung, spleen and bone with histological confirmation. Illustrative materials—including imaging series, tumor growth trajectories and endpoint summaries—are available on request and are refreshed as further programs conclude.

Why Choose Alfa Cytology?

Sponsors select Alfa Cytology for this model because a fast, matrix-building bone tumor rewards exactly the operational strengths this team has built:

• A disciplined bone-surgery group delivering consistent, high-survival intratibial implantation.
• STR-verified Saos-2 and stably luciferase-labeled Saos-2-luc banks ready for immediate study start.
• Dual-modality monitoring that pairs quantitative bioluminescence with CT documentation of osteocondensation.
• A faithfully osteoblastic, mineralizing primary tumor that mirrors bone-forming human disease.
• Structured schedules calibrated to brisk NSG kinetics, with humane endpoints defined up front.
• A configurable endpoint menu spanning efficacy, multi-organ metastasis counting, histopathology and molecular analysis.
• Responsive, single-point project communication with milestone-based progress reporting.
• An exclusively preclinical mandate, with all studies designed, conducted and reported as non-clinical research.

Contact Us

If the Saos-2 / Saos-2-luc orthotopic sarcoma model aligns with your next preclinical objective, contact us to share your compound, timeline and preferred endpoints. The Alfa Cytology team will reply with a customized plan covering model setup, imaging cadence and analysis strategy—reach out today and move your program forward with confidence.

For research use only. Not intended for any clinical use.